Stay updated on ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.

Latest updates to the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe record history shows minor site updates: a new Revision: v3.3.3 and removal of the HHS Vulnerability Disclosure and Revision: v3.3.2 from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedA new revision entry v3.3.2 was added to the record history. The older revision v3.2.0 was removed from the history list.SummaryDifference0.1%

- Check43 days agoChange DetectedThe government funding status notice banner was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check65 days agoChange DetectedThis change appears to be a cosmetic update to the Record History view with no modification to core study information; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check86 days agoChange Detected- Added a prominent notice about potential outdated information due to lapse in funding and updated operating status references, plus a link to operating-status details. - Updated version to v3.2.0. - Removed old version reference v3.1.0.SummaryDifference12%

- Check94 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.3%

Stay in the know with updates to ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.